{"entity":{"id":"nct03778047","kind":"trial","name":"A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch","aka":[],"tldr":"A phase 1 trial of Deutenzalutamide run by Hinova Pharmaceuticals Inc., completed.","summary":"A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch is a phase 1 interventional study registered as NCT03778047 by Hinova Pharmaceuticals Inc., with 10 participants enrolled, started 2018-02-07. Conditions recorded: Metastatic Castration Resistant Prostate Cancer. Interventions recorded: Enzalutamide and HC1119.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03778047","url":"https://clinicaltrials.gov/study/NCT03778047"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["deutenzalutamide"],"companies":["hinova-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03778047","phase":"1","setting":"A Clinical Study for Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Hinova Pharmaceuticals Inc.","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03778047/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"deutenzalutamide","kind":"drug","name":"Deutenzalutamide","route":"/drugs/deutenzalutamide/"}],"company":[{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/"}]}}